Frontiers in Immunology (Mar 2018)
Corrigendum: Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study
- Paola Queirolo,
- Beatrice Dozin,
- Anna Morabito,
- Barbara Banelli,
- Barbara Banelli,
- Patrizia Piccioli,
- Cristiana Fava,
- Claudio Leo,
- Roberta Carosio,
- Stefania Laurent,
- Vincenzo Fontana,
- Pier Francesco Ferrucci,
- Chiara Martinoli,
- Emilia Cocorocchio,
- Angelo Battaglia,
- Paolo A. Ascierto,
- Mariaelena Capone,
- Ester Simeone,
- Federica De Galitiis,
- Elena Pagani,
- Gian Carlo Antonini Cappellini,
- Paolo Marchetti,
- Paolo Marchetti,
- Michele Guida,
- Stefania Tommasi,
- Mario Mandalà,
- Barbara Merelli,
- Pietro Quaglino,
- Paolo Fava,
- Massimo Guidoboni,
- Massimo Romani,
- Francesco Spagnolo,
- Maria Pia Pistillo
Affiliations
- Paola Queirolo
- Department of Medical Oncology, IRCCS AOU San Martino-IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
- Beatrice Dozin
- Unit of Clinical Epidemiology, IRCCS AOU San Martino-IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
- Anna Morabito
- Unit of Tumor Epigenetics, IRCCS AOU San Martino-IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
- Barbara Banelli
- Unit of Tumor Epigenetics, IRCCS AOU San Martino-IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
- Barbara Banelli
- Department of Health Sciences, University of Genova, Genova, Italy
- Patrizia Piccioli
- Unit of Cellular Biology, IRCCS AOU San Martino-IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
- Cristiana Fava
- Department of Medical Oncology, IRCCS AOU San Martino-IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
- Claudio Leo
- Department of Medical Oncology, IRCCS AOU San Martino-IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
- Roberta Carosio
- Unit of Tumor Epigenetics, IRCCS AOU San Martino-IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
- Stefania Laurent
- Intergruppo Melanoma Italiano (IMI) and Department of Internal Medicine, University of Genova, Genova, Italy
- Vincenzo Fontana
- Unit of Clinical Epidemiology, IRCCS AOU San Martino-IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
- Pier Francesco Ferrucci
- Oncology of Melanoma Unit, European Institute of Oncology, Milan, Italy
- Chiara Martinoli
- Oncology of Melanoma Unit, European Institute of Oncology, Milan, Italy
- Emilia Cocorocchio
- Oncology of Melanoma Unit, European Institute of Oncology, Milan, Italy
- Angelo Battaglia
- Oncology of Melanoma Unit, European Institute of Oncology, Milan, Italy
- Paolo A. Ascierto
- Melanoma, Cancer Immunotherapy and Innovative Therapy Unit, Istituto Nazionale Tumori Fondazione ‘G. Pascale’, Naples, Italy
- Mariaelena Capone
- Melanoma, Cancer Immunotherapy and Innovative Therapy Unit, Istituto Nazionale Tumori Fondazione ‘G. Pascale’, Naples, Italy
- Ester Simeone
- Melanoma, Cancer Immunotherapy and Innovative Therapy Unit, Istituto Nazionale Tumori Fondazione ‘G. Pascale’, Naples, Italy
- Federica De Galitiis
- Istituto Dermopatico dell’Immacolata IDI-IRCCS, Rome, Italy
- Elena Pagani
- Istituto Dermopatico dell’Immacolata IDI-IRCCS, Rome, Italy
- Gian Carlo Antonini Cappellini
- Istituto Dermopatico dell’Immacolata IDI-IRCCS, Rome, Italy
- Paolo Marchetti
- Istituto Dermopatico dell’Immacolata IDI-IRCCS, Rome, Italy
- Paolo Marchetti
- 0Medical Oncology, Sant’Andrea Hospital, Sapienza University of Rome, Rome, Italy
- Michele Guida
- 1Department of Medical Oncology, Molecular Genetics Laboratory, IRCCS Istituto Tumori “Giovanni Paolo II,”Bari, Italy
- Stefania Tommasi
- 1Department of Medical Oncology, Molecular Genetics Laboratory, IRCCS Istituto Tumori “Giovanni Paolo II,”Bari, Italy
- Mario Mandalà
- 2Unit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, Bergamo, Italy
- Barbara Merelli
- 2Unit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, Bergamo, Italy
- Pietro Quaglino
- 3Dermatologic Clinic, Department of Medical Sciences, University of Turin, Turin, Italy
- Paolo Fava
- 3Dermatologic Clinic, Department of Medical Sciences, University of Turin, Turin, Italy
- Massimo Guidoboni
- 4Immunotherapy and Cell Therapy, IRCCS-IRST, Meldola, Italy
- Massimo Romani
- Unit of Tumor Epigenetics, IRCCS AOU San Martino-IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
- Francesco Spagnolo
- Department of Medical Oncology, IRCCS AOU San Martino-IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
- Maria Pia Pistillo
- Unit of Tumor Epigenetics, IRCCS AOU San Martino-IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
- DOI
- https://doi.org/10.3389/fimmu.2018.00403
- Journal volume & issue
-
Vol. 9
Abstract
No abstracts available.Keywords
- CTLA-4 variants
- melanoma
- ipilimumab
- best overall response
- overall survival
- predictive/prognostic factor